{
    "clinical_study": {
        "@rank": "82454", 
        "acronym": "CAESAR", 
        "arm_group": [
            {
                "arm_group_label": "Mild-to-Moderate Asthma", 
                "description": "Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines."
            }, 
            {
                "arm_group_label": "Severe Asthma", 
                "description": "Major Criteria: (1 required)\nTreatment with continuous or near-continuous oral corticosteroids for at least 6 of the previous 12 months\nTreatment with high-dose inhaled corticosteroids* for at least 10 of the previous 12 months\nMinor Criteria: (2 required)\nDaily treatment with an asthma controller medication in addition to inhaled corticosteroids (i.e., long-acting beta-agonists, montelukast, theophylline), or\nAsthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or\nPersistent airway obstruction with baseline FEV1 <80% predicted, or\n\u2265 1 urgent visits for asthma in the previous 12 months, or\n\u2265 3 systemic corticosteroid bursts in the previous 12 months, or\nPrompt deterioration with a reduction in oral or inhaled corticosteroid dose, or\nA near-fatal asthma event (i.e., intubation) in the past."
            }, 
            {
                "arm_group_label": "Healthy Controls", 
                "description": "Those without asthma or other chronic lung disease."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to characterize subjects in terms of their sputum phenotype. The\n      purpose of this study is to learn more about the impact of having abnormally elastic sputum\n      on asthma severity by comparing subjects with severe as well as mild/moderate asthma to\n      healthy controls. The characterization will include medical history, pulmonary function\n      testing, imaging of the lungs and biospecimen collection."
        }, 
        "brief_title": "Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program", 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  FEV1 bronchodilator reversibility \u226512% or airway hyperresponsiveness reflected by a\n             methacholine PC20 \u226416 mg/mL\n\n          -  An exception will be made for enrollees whose FEV1 is < 50% predicted (<70% in\n             children aged 6 to 17 years), precluding methacholine challenge testing. If\n             bronchodilator reversibility is <12% in these participants, a diagnosis of asthma\n             acceptable to the investigator is sufficient for inclusion in CAESAR.\n\n        Exclusion Criteria:\n\n          -  Pregnancy,\n\n          -  Current smoking,\n\n          -  Smoking history > 10 pack years if \u226530 years of age, or smoking history > 5 pack\n             years if <30 years of age,\n\n          -  Other chronic pulmonary disorders associated with asthma-like symptoms, including\n             (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic\n             bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms\n             and at the PI's discretion), severe scoliosis or chest wall deformities that affect\n             lung function, or congenital disorders of the lungs or airways,\n\n          -  History of premature birth before 35 weeks gestation,\n\n          -  Planning to relocate from the clinical center area before study completion,\n\n          -  Any other criteria that place the subject at unnecessary risk according to the\n             judgment of the Principal Investigator and/or attending physician(s) of record, or\n\n          -  Currently participating in an investigational drug trial.\n\n        Healthy Controls:\n\n        Inclusion criteria: Healthy subjects between the age of 18y and 65y. At least 3 of the 7\n        subjects per center should be aged 35y or older.\n\n        Exclusion criteria\n\n          -  History of chronic diseases that affect the lungs.\n\n          -  A history suggestive of allergic rhinitis, eczema or chronic sinusitis.\n\n          -  An improvement in FEV1 of more than 12% following 4 puffs of albuterol.\n\n          -  Smoking history > 10 pack years if \u226530 years of age, or smoking history > 5 pack\n             years if <30 years of age, or any smoking within the past year.\n\n          -  Respiratory tract infection within the past 4 weeks.\n\n          -  Pregnancy.\n\n          -  History of premature birth (<35 weeks)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "A diverse sample of subjects with asthma is needed to gain better understanding of asthma\n        and its endotypes. CAESAR will therefore enroll subjects between 18 and 65 years with a\n        physician diagnosis of asthma as well as a group of healthy subjects. The target\n        recruitment goal for UCSF is 50 adults with asthma and 25 healthy controls (age 18 and\n        older). Within the asthma group, an attempt will be made to enroll 60% of subjects with\n        severe with the rest of the subjects mild to moderate asthma.Within the cohort, an attempt\n        will be made to enroll at least 50% females and 10% minorities."
            }
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103348", 
            "org_study_id": "14-13242"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Severe asthma", 
            "Sputum", 
            "Mucolysis"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "contact": {
                "last_name": "John V Fahy, M.D. M.Sc", 
                "phone": "415-502-4849"
            }, 
            "contact_backup": {
                "email": "eleanor.dunican@ucsf.edu", 
                "last_name": "Eleanor M Dunican, MB BCh", 
                "phone": "415 5685929"
            }, 
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94143"
                }, 
                "name": "University of California, San Francisco"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program", 
        "other_outcome": {
            "description": "Examining CT chest in asthmatics for evidence of retained mucus.", 
            "measure": "CT Chest", 
            "safety_issue": "Yes", 
            "time_frame": "Cross sectional over 4-6 weeks"
        }, 
        "overall_contact": {
            "email": "eleanor.dunican@ucsf.edu", 
            "last_name": "Eleanor M Dunican, MB BCh"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "John V Fahy, M.D. M.SC.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Lung function as a measure of asthma severity.", 
            "measure": "Lung function", 
            "safety_issue": "Yes", 
            "time_frame": "Cross sectional over 4-6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103348"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "John V. Fahy", 
            "investigator_title": "M.D. M.SC.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Changes in inflammatory cellular markers in sputum and blood. We will measure various indicators of airway inflammation and compare them with various phenotypic characteristics.", 
            "measure": "Inflammatory cellular markers", 
            "safety_issue": "Yes", 
            "time_frame": "Cross sectional over 4-6 weeks"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}